---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-088689"
form_type: "8-K"
ticker: "TMDX"
cik: "0001756262"
company_name: "TransMedics Group, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:27:20.694624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransMedics Q2 revenue $114.3M (+118% YoY), net income $12.2M, raises FY guidance

## Summary
- Revenue $114.3M (+118% YoY); net income $12.2M ($0.35 diluted EPS) vs net loss $1.0M.
- Gross margin 61% (down from 70% YoY) due to higher service revenue mix.
- Operating expenses $56.8M (incl $7.3M stock comp) vs $37.6M prior year; driven by R&D and growth.
- Raises FY2024 revenue guidance to $425M-$445M (76%-84% growth) from prior $390M-$400M.
- Cash $362.8M as of June 30; owned 15 aircraft, purchased 2 more in July 2024.

## SEC filing metadata
- accession: 0000950170-24-088689
- form_type: 8-K
- ticker: TMDX
- cik: 0001756262
- company_name: TransMedics Group, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1756262/000095017024088689/0000950170-24-088689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1756262/000095017024088689/tmdx-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-088689
- JSON: https://secwatch.observer/filing/0000950170-24-088689.json
- Plain text: https://secwatch.observer/filing/0000950170-24-088689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.